User-Driven Strategy for In Silico Screening of Reversed-Phase Liquid Chromatography Conditions for Known Pharmaceutical-Related Small Molecules.
method development
multi-criteria decision analysis
response surface methodology
reversed-phase liquid chromatography
small pharmaceutical compounds
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
28 Nov 2022
28 Nov 2022
Historique:
received:
30
09
2022
revised:
21
11
2022
accepted:
24
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
In the pharmaceutical field, and more precisely in quality control laboratories, robust liquid chromatographic methods are needed to separate and analyze mixtures of compounds. The development of such chromatographic methods for new mixtures can result in a long and tedious process even while using the design of experiments methodology. However, developments could be accelerated with the help of in silico screening. In this work, the usefulness of a strategy combining response surface methodology (RSM) followed by multicriteria decision analysis (MCDA) applied to predictions from a quantitative structure-retention relationship (QSRR) model is demonstrated. The developed strategy shows that selecting equations for the retention time prediction models based on the pKa of the compound allows flexibility in the models. The MCDA developed is shown to help to make decisions on different criteria while being robust to the user's decision on the weights for each criterion. This strategy is proposed for the screening phase of the method lifecycle. The strategy offers the possibility to the user to select chromatographic conditions based on multiple criteria without being too sensitive to the importance given to them. The conditions with the highest desirability are defined as the starting point for further optimization steps.
Identifiants
pubmed: 36500399
pii: molecules27238306
doi: 10.3390/molecules27238306
pmc: PMC9735675
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fund for Scientific Research
ID : 30897864
Références
Anal Chim Acta. 2016 Apr 15;916:8-16
pubmed: 27016433
Talanta. 2010 Jun 15;81(4-5):1711-8
pubmed: 20441962
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Dec 1;910:84-94
pubmed: 22341354
Anal Chem. 2016 Jan 5;88(1):997-1002
pubmed: 26607659
Anal Chem. 1985 Dec;57(14):2971-8
pubmed: 4083492
Anal Chem. 2003 Mar 1;75(5):1039-48
pubmed: 12641221
Metabolites. 2020 Jun 09;10(6):
pubmed: 32526851
J Chromatogr A. 2007 Jul 27;1158(1-2):273-305
pubmed: 17499256
Anal Chem. 2021 Jan 12;93(1):228-256
pubmed: 33085452
J Proteome Res. 2005 Mar-Apr;4(2):555-63
pubmed: 15822934
Data Brief. 2022 Mar 04;42:108017
pubmed: 35310817
J Chromatogr A. 2021 Jan 4;1635:461743
pubmed: 33260022
J Chromatogr A. 2010 Jun 11;1217(24):3794-803
pubmed: 20444458
Talanta. 2008 Sep 15;76(5):965-77
pubmed: 18761143
J Sep Sci. 2021 Jan;44(1):88-114
pubmed: 33058527
J Chromatogr A. 2004 Dec 10;1060(1-2):77-116
pubmed: 15628153
Chem Rev. 2007 Jul;107(7):3212-46
pubmed: 17595149
Talanta. 2014 Jun;124:123-38
pubmed: 24767454
J Pharm Biomed Anal. 2014 Jan;88:401-9
pubmed: 24176744
Anal Chim Acta. 2009 May 29;642(1-2):257-65
pubmed: 19427484
J Chromatogr A. 2014 Sep 5;1358:145-54
pubmed: 25039066
Anal Chem. 2017 Feb 7;89(3):1870-1878
pubmed: 28208251
Talanta. 2019 Mar 1;194:941-959
pubmed: 30609628
Metabolomics. 2015;11(3):696-706
pubmed: 25972771
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Dec 1;910:2-13
pubmed: 22333438
J Pharm Biomed Anal. 2021 Sep 5;203:114203
pubmed: 34153936
Anal Chem. 2015 Jul 21;87(14):7241-9
pubmed: 26096131